Virtual training adapted to type 1 diabetic patients
A major by-product of the ongoing COVID-19 pandemic has been the adoption of telemedicine tools to help patients while reducing the need and risk for in-person medical appointments.
In data presented at the 2021 American Diabetes Association Virtual Meeting, researchers looked at how virtual training is helping patients with type 1 diabetes.
Even with recent advances in technology, researchers have yet to close the gap in finding optimal glycemic control for patients with type 1 diabetes. However, closed-loop hybrid systems equipped with automated adjustments algorithms derived from basal insulin delivery could improve this without adding additional therapeutic burdens or educational investments.
A team, led by Adrian E. Proietti, evaluated the effectiveness of HCL systems in patients with type 1 diabetes in Latin America who received virtual training.
In the prospective analysis of observational data, the researchers looked at 104 consecutive patients with type 1 diabetes who started treatment with the MiniMed ™ 670G system in Argentina. The mean age of the patient population was 32.8% and each patient was previously on MDI + SMBG (26%), MDI + isCGM (12.5%), CSII + SMBG (9.6%), CSII + isCGM (2.9%) and SAP-TS (49%).
The initial IGM was 7.3 ± 0.8%.
Researchers carried out baseline and follow-up visits on days 28, 90 and 180. Training and follow-up were carried out entirely virtual. Time in the 70-180 mg / dl range significantly increased regardless of previous treatment, from 62.1 ± 14.8% at baseline to 74.6 ± 8.6%, 74.2 ± 9 , 8% and 74.3 ± 9.6% on days 28, 90 and 180 respectively (P
In addition, mean glucose levels decreased from 166.1 mg / dL at baseline to 152.9 mg / dL (P P
Sensor wear time and auto mode usage were 89.1% and 88.6%, respectively, at the end of the study.
“Our results confirm that use of the MiniMed ™ 670 System allows patients to achieve glycemic control within recommended targets in an unselected population in Argentina,” wrote the authors. “Virtual education appears to be suitable for training patients on HCL therapy during the current COVID-19 pandemic situation. “
Telemedicine during COVID-19
Earlier this year, a survey found great satisfaction with telehealth visits to endocrinology providers and patients.
In fact, many patients with chronic endocrine health issues requiring close monitoring have indicated that they want to continue with follow-up telemedicine visits after the pandemic has ended.
Among the patients surveyed, 65% expressed the wish to continue telemedicine after the pandemic. Additionally, 42% of patients preferred video tours, while 37% preferred phone calls. Up to 77% indicated that the quality of care with telemedicine, regardless of the modality, was almost the same as that of in-person visits.
In terms of time spent visiting, 45% said they liked spending less time on telemedicine.
A majority (54%) noted that the length of their telemedicine visit was about the same as in person, and yet 54% also believed they spent less time on telemedicine.
Even more, an overwhelming majority (90%) indicated that all of their questions and concerns were handled by telemedicine.
However, a smaller proportion of patients reported no connectivity issues (37%) or technical difficulties (25%).
The study, “Six-month glycemic control with a closed-loop hybrid system in patients with type 1 diabetes during the COVID-19 pandemic in Argentina,” was posted online by ADA.